ProQR Therapeutics

ProQR Therapeutics NV is a clinical stage biopharmaceutical company. It is engaged in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases with a focus on inherited retinal diseases, such as Leber congenital amaurosis 10, Usher syndrome type 2, and autosomal dominant retinitis pigmentosa. Its product pipeline includes Sepofarsen, Ultevursen, Axiomer technology, and RNA therapy. The company was founded by Daniel Anton de Boer, Gerard J. Platenburg, Henri A. Termeer, and Domenico Valerio on February 21, 2012 and is headquartered in Leiden, the Netherlands.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ProQR Therapeutics NV is a clinical stage biopharmaceutical company, which engages in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases with a focus on inherited retinal diseases. The company was founded by Daniel Anton de Boer, Gerard J. Platenburg, Henri A. Termeer, and Domenico Valerio on February 21, 2012, and is headquartered in Leiden, the Netherlands.

PRQR stock is rocketing up this morning, carrying the momentum of a press release from earlier in the week. Here's what you need to know.

PRQR Stock: 7 Things to Know About High-Flying ProQR Therapeutics

The stock price of ProQR Therapeutics NV (NASDAQ: PRQR) has increased by over 66% intraday. This is why it happened.

PRQR Stock Price Increased Over 66% Intraday: Why It Happened

Cellect Biotechnology Ltd

Evofem Biosciences Inc

F-Star Therapeutics Inc

Immutep Ltd

Cellect Biotechnology Ltd. (NASDAQ: APOP), Immutep Limited (NASDAQ: IMMP), F-star Therapeutics, Inc. (NASDAQ: FSTX), ProQR Therapeutics N.V.

Why Cellect, Immutep, F-star, ProQR and Evofem Are Moving Thursday

ProQR Therapeutics NV (NASDAQ: PRQR) shares are trading higher by more than 52% after the company reported results Wednesday from its trial of QR-421a in Usher Syndrome, though the stock did not surge initially. ProQR is a biopharmaceutical company that develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.

Why PRQR Stock And APOP Stock Are Popping Off Today

The company reported positive results from a clinical trial.

Why ProQR Therapeutics Stock Is Popping Today

ProQR Therapeutics NV (NASDAQ: PRQR) has announced results from a planned analysis of its Phase 1/2 Stellar trial evaluating QR-421a in adults with Usher syndrome and non-syndromic retinitis pigmentosa due to USH2A exon 13 mutations. In the trial, single-dose QR-421a demonstrated benefit on multiple vision measures that moved in concordance, including visual acuity, visual fields, and optical coherence tomography retinal imaging.

ProQR Therapeutics Is Trading Higher On Positive QR-421a Data In Usher Syndrome

LEIDEN, Netherlands & CAMBRIDGE, Mass., March 24, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced results from a planned analysis of its Phase 1/2 Stellar trial of QR-421a in adults with Usher syndrome and non-syndromic retinitis pigmentosa (nsRP) due to USH2A exon 13 mutations. In the trial, QR-421a demonstrated benefit on multiple measures of vision that moved in concordance, including visual acuity, visual fields, and optical coherence tomography (OCT) retinal imaging, after a single dose. QR-421a was observed to be well tolerated with no serious adverse events reported. Based on these findings, the Company plans to advance QR-421a to two parallel pivotal Phase 2/3 trials by year end 2021 – one in early-moderate patients, one in advanced patients.

ProQR Announces Positive Results from Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trials

Bristol-Myers

Pfizer

BioCryst Pharmaceuticals

Marker Therapeutics Inc

Pacira Pharmaceuticals

Rubius Therapeutics Inc

Zealand Pharma

Biotech stocks reversed course in the week ended March 19 amid mixed news flow on data readouts and lackluster broader market performance. Rubius Therapeutics, Inc. (NASDAQ: RUBY) was among the biggest gainers of the week after the biopharma reported positive Phase 1/2 data for its RTX-240 in solid tumors.

FDA Decisions For Pfizer, Eli Lilly And Bluebird Bio, Bristol-Meyers Squibb, Plus New Data And Earnings

Today, we revisit ProQR Therapeutics for the first time since September. This Netherlands-based biotech concern is universally loved by analysts but isn't getting enough attention from investors, in my opinion.

Pounding The Table For ProQR Therapeutics

LEIDEN, Netherlands & CAMBRIDGE, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced that Company management will present during a fireside chat at the upcoming virtual HC Wainwright Global Life Sciences Conference. A webcast of the presentation will be accessible on demand from the “Investors & Media” section of ProQR's website ( www.proqr.com ) under ‘Events', beginning March 9, 2021.

ProQR Announces Webcast of Presentation at Upcoming HC Wainwright Global Life Sciences Conference

LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today reported its financial and operating results for the fourth quarter and full year ended December 31, 2020 and provided a business update.

ProQR Announces Fourth Quarter and Full Year 2020 Operating and Financial Results

LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced that the Company will host an Expert Perspectives call on February 22, 2021 at 12:00pm EST. The call will feature a discussion between Aniz Girach, MD, Chief Medical Officer of ProQR Therapeutics and Paul Yang, MD, PhD about disease education and endpoints in Usher syndrome and non-syndromic Retinitis Pigmentosa (nsRP).  Areas of focus for the session will include which vision measures are most informative in the context of this disease setting, the role of patient baseline and disease progression, and an overview of the objectives of the Phase 1/2 Stellar trial of QR-421a.

ProQR Announces Expert Perspectives Call on Disease Education and Endpoints in Usher Syndrome

LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) --  ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced it has completed patient enrollment in its Phase 2/3 Illuminate study of sepofarsen for the treatment of Leber Congenital Amaurosis 10 (LCA10) due to the p.Cys998X mutation in the CEP290 gene. With enrollment completed, top-line results are expected in the first half (H1) of 2022.

ProQR Completes Enrollment of its Pivotal Trial of Sepofarsen for the Treatment of LCA10

LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 18, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced that Company management will present during a fireside chat at the upcoming HC Wainwright Virtual BIOCONNECT 2021 Conference. A webcast of the presentation will be accessible from the “Investors & Media” section of ProQR's website (www.proqr.com) under ‘Events', beginning January 11, 2021.

ProQR Announces Webcast of Presentation at Upcoming HC Wainwright BIOCONNECT Conference

LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 18, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced that Company management will present during a fireside chat at the upcoming 3rd Annual Evercore ISI Virtual HealthCONx Conference. The presentation will be webcast live on December 2, 2020 at 3:55pm EST.

ProQR to Present at 3rd Annual Evercore ISI Virtual HealthCONx Conference

LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today reported its financial and operating results for the third quarter ended September 30, 2020 and provided a business update, including updated timeline guidance for the Company's clinical stage programs.

ProQR Announces Third Quarter 2020 Operating and Financial Results

LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced virtual poster presentations at the Annual Meeting of the American Academy of Ophthalmology (AAO) held November 13-15, 2020.

ProQR Announces Virtual Presentations at American Academy of Ophthalmology (AAO)

Proven leader with deep worldwide ophthalmology experience, including multiple approvals globally Proven leader with deep worldwide ophthalmology experience, including multiple approvals globally

ProQR Appoints Naveed Shams, MD, PhD as Chief Scientific Officer

LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept.  24, 2020  (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced virtual presentations at the Ophthalmology Futures Retina Forum, European Society of Retina Specialists (Euretina) congress and the Annual Meeting of the American Academy of Optometry (AAOpt).

ProQR Announces Virtual Presentations at Scientific Conferences

LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept.  03, 2020  (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA medicines for inherited retinal diseases (IRDs), today announced that Company management will participate in the following upcoming investor conferences:

ProQR to Participate in Upcoming Investor Conferences

ProQR Therapeutics: Bringing A New Cure To The Market

LEIDEN, Netherlands & CAMBRIDGE, Mass., Aug.  06, 2020  (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today reported its financial and operating results for the second quarter ended June 30, 2020 and provided a business update.

ProQR Announces Second Quarter 2020 Operating and Financial Results

LEIDEN, Netherlands & CAMBRIDGE, Mass., July  21, 2020  (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced the strengthening of the Company’s Scientific Advisory Board (SAB) with new members. The SAB members serve as strategic advisors to the Company as it continues to advance its pipeline of RNA therapeutics and its proprietary technology platforms.

ProQR Strengthens Scientific Advisory Board with Leaders in Inherited Retinal Disease and RNA Therapy

LEIDEN, Netherlands & CAMBRIDGE, Mass. , July  14, 2020  (GLOBE NEWSWIRE) --   ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced that it has entered into a $30 million convertible debt financing agreement with Pontifax Medison Debt Financing, the healthcare-dedicated venture and debt fund of the Pontifax life science funds.

ProQR Announces $30 Million Strategic Convertible Debt Financing Agreement with Pontifax Ventures

Call on July 20 will include a snapshot from the ongoing InSight open-label extension study of sepofarsen, including preliminary second eye treatment data Call on July 20 will include a snapshot from the ongoing InSight open-label extension study of sepofarsen, including preliminary second eye treatment data

News for ProQR Therapeutics Stock (PRQR)